Viatris reported Q3 revenues of $3.75B and raised its 2026 guidance. The company also received regulatory approvals and announced the planned acquisition of Pacira BioSciences, coupled with $717M in capital returned to shareholders.
Viatris reported Q3 revenues of $3.75B and raised its 2026 guidance. The company also received regulatory approvals and announced the planned acquisition of Pacira BioSciences, coupled with $717M in capital returned to shareholders.